Suppr超能文献

对乙酰氨基酚栓剂制剂与片剂相比的相对生物利用度

[Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets].

作者信息

Blume H, Ali S L, Elze M, Krämer J, Wendt G, Scholz M E

机构信息

Zentrallaboratorium Deutsher Apotheker, Eschborn.

出版信息

Arzneimittelforschung. 1994 Dec;44(12):1333-8.

PMID:7848353
Abstract

Relative Bioavailability of Paracetamol as Suppositories Compared to Tablets. The relative bioavailability of paracetamol (CAS 103-90-2) in ben-u-ron 500 mg and ben-u-ron 1000 mg suppositories (test formulations) was compared with that of Benuron tablets 500 mg (reference product) in an open, intraindividual, 3-period-changeover-study in 18 healthy subjects. Plasma concentrations of paracetamol were determined using a specific and sensitive HPLC method with UV detection. For the assessment of bioavailability AUC, Cmax, tmax and HVD were used as pharmacokinetic characteristics. Bioequivalence of the rectal formulations was tested by calculating 90% confidence intervals using the Two-one-sided-t-tests-procedure and log-transformed data of AUC and Cmax. For AUC the confidence intervals were required to be in the 80 and 125% range, for Cmax between 70 and 143% (inclusion rule). Data from 17 subjects could be evaluated. Bioavailability of paracetamol was 89 and 90% for the 500 and 1000 mg suppositories, respectively compared with that of the 500 mg reference tablets. Mean maximum paracetamol plasma concentrations (Cmax) were 3.55 and 6.02 or 7.16 mg/l after administration of the 500 and 1000 mg suppositories or the 500 mg tablets, respectively. These maximum concentrations were achieved 2.0, 2.7 and 0.6 h (tmax) after administration of the respective preparations. The corresponding HVD values were 4.3, 5.2 and 2.0 h, respectively. After dose adjustment of the results for the 1000 mg suppositories relative bioavailabilities of paracetamol from both rectal formulations exceeded 80% of that from the tablets.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对乙酰氨基酚栓剂与片剂的相对生物利用度。在18名健康受试者中进行了一项开放、个体内、3期交叉研究,比较了对乙酰氨基酚(CAS 103-90-2)在500毫克和1000毫克贝努龙栓剂(试验制剂)中的相对生物利用度与500毫克贝努龙片剂(参比产品)的相对生物利用度。采用具有紫外检测的特异性灵敏高效液相色谱法测定对乙酰氨基酚的血浆浓度。为评估生物利用度,将AUC、Cmax、tmax和HVD用作药代动力学特征。通过使用双单侧t检验程序并对AUC和Cmax的对数转换数据计算90%置信区间,来测试直肠制剂的生物等效性。对于AUC,要求置信区间在80%至125%范围内,对于Cmax在70%至143%之间(纳入规则)。可对17名受试者的数据进行评估。与500毫克参比片剂相比,500毫克和1000毫克栓剂中对乙酰氨基酚的生物利用度分别为89%和90%。分别给予500毫克和1000毫克栓剂或500毫克片剂后,对乙酰氨基酚的平均最大血浆浓度(Cmax)分别为3.55、6.02或7.16毫克/升。这些最大浓度分别在给予相应制剂后2.0、2.7和0.6小时(tmax)达到。相应的HVD值分别为4.3、5.2和2.0小时。在对1000毫克栓剂的结果进行剂量调整后,两种直肠制剂中对乙酰氨基酚的相对生物利用度均超过片剂的80%。(摘要截断于250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验